Suppr超能文献

海绵状血管畸形放射外科治疗后的重复放射外科治疗

Repeat Radiosurgery Treatment After Cavernous Malformation Radiosurgery.

作者信息

Nagy Gábor, Yianni John, Bhattacharyya Debapriya, Rowe Jeremy G, Kemeny Andras A, Radatz Matthias W R

机构信息

National Institute of Clinical Neurosciences, Budapest, Hungary.

Department of Neurosurgery, Royal Hallamshire Hospital, Sheffield, United Kingdom; National Centre for Stereotactic Radiosurgery, Royal Hallamshire Hospital, Sheffield, United Kingdom; Thornbury Radiosurgery Centre, Sheffield, United Kingdom.

出版信息

World Neurosurg. 2018 Oct;118:e296-e303. doi: 10.1016/j.wneu.2018.06.183. Epub 2018 Jun 30.

Abstract

OBJECTIVE

Of cavernous malformations (CMs) treated with radiosurgery (RS), 5% bleed after 2-year initial latency period. This rate is similar to failure rate of RS for other pathologies, which often require repeat RS for favorable outcome. The aim of this pilot study was to define failure of CM RS and to assess safety of second RS.

METHODS

Retrospective analysis was performed of 7 of 345 CMs retreated with RS; 6 CMs were deep-seated, and 1 was superficial. Median time between the 2 treatments was 8 years (range, 3-16 years), and median follow-up time after second RS was 3 years (range, 1-9 years).

RESULTS

Following the 2-year latency period after RS, 6% of deep-seated and 5% of hemispheric CMs, and 6% of deep-seated and 2% of hemispheric lesions caused transient neurologic deficits without hemorrhage. A second treatment was indicated for rebleed in 5 cases and for recurrent transient neurologic deficits in 2 cases. Prescribed dose was 15 Gy (range, 12-20 Gy) at first treatment and 12 Gy (range, 12-18 Gy) at second treatment. Target volumes were 692 mm (range, 54-2400 mm) and 935 mm (range, 150-1550 mm) at first and second treatments, respectively, and treatment volumes were 811 mm (range, 79-2500 mm) and 962 mm (range, 194-1750 mm), respectively. Differences in treatment parameters were not significant. Reason for failure was inaccurate target definition in only 2 cases. There were no bleeds, morbidity, or mortality after second RS.

CONCLUSIONS

Second RS applied to previously treated CMs is safe and may be effective. Further investigations are needed to verify these findings and assess long-term benefit of second RS.

摘要

目的

在接受放射外科治疗(RS)的海绵状血管畸形(CMs)中,5%在2年的初始潜伏期后出血。该比率与RS治疗其他病变的失败率相似,后者通常需要重复RS以获得良好疗效。本前瞻性研究的目的是定义CM RS的失败情况并评估二次RS的安全性。

方法

对345例接受RS再次治疗的CMs中的7例进行回顾性分析;6例CMs为深部病变,1例为浅表病变。两次治疗之间的中位时间为8年(范围3 - 16年),二次RS后的中位随访时间为3年(范围1 - 9年)。

结果

在RS后的2年潜伏期后,6%的深部CMs和5%的半球CMs以及6%的深部病变和2%的半球病变导致无出血的短暂性神经功能缺损。5例因再出血、2例因复发性短暂性神经功能缺损而需要进行二次治疗。首次治疗时规定剂量为15 Gy(范围12 - 20 Gy),二次治疗时为12 Gy(范围12 - 18 Gy)。首次和二次治疗时的靶体积分别为692 mm(范围54 - 2400 mm)和935 mm(范围150 - 1550 mm),治疗体积分别为811 mm(范围79 - 2500 mm)和962 mm(范围194 - 1750 mm)。治疗参数差异无统计学意义。仅2例失败原因是靶区定义不准确。二次RS后无出血、并发症或死亡发生。

结论

对先前接受过治疗的CMs进行二次RS是安全的,可能有效。需要进一步研究以验证这些发现并评估二次RS的长期益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验